Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- FDMT
- Price
- 3.47
- Stock movement up
- +0.05 (1.46%)
- Company name
- 4D Molecular Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 160.41M
- Ent value
- 23.95M
- Price/Sales
- 9435.89
- Price/Book
- 0.29
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 31.97%
- 1 year return
- -86.20%
- 3 year return
- -23.69%
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-05-29
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
FDMT does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 9435.89 |
| Price to Book | 0.29 |
| EV to Sales | 1408.89 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 46.23M |
| EPS (TTM) | -2.58 |
| FCF per share (TTM) | -2.09 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 17.00K |
| Gross profit (TTM) | -7.44M |
| Operating income (TTM) | -168.38M |
| Net income (TTM) | -143.48M |
| EPS (TTM) | -2.58 |
| EPS (1y forward) | -3.61 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -43747.06% |
| Operating margin (TTM) | -214748.36% |
| Profit margin (TTM) | -214748.36% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 187.54M |
| Net receivables | 0.00 |
| Total current assets | 510.76M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 604.03M |
| Accounts payable | 2.92M |
| Short/Current long term debt | 24.83M |
| Total current liabilities | 29.46M |
| Total liabilities | 51.08M |
| Shareholder's equity | 552.95M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -113.37M |
| Capital expenditures (TTM) | 2.67M |
| Free cash flow (TTM) | -116.04M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -25.95% |
| Return on Assets | -23.75% |
| Return on Invested Capital | -25.71% |
| Cash Return on Invested Capital | -20.79% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 3.44 |
| Daily high | 3.50 |
| Daily low | 3.40 |
| Daily Volume | 292K |
| All-time high | 52.67 |
| 1y analyst estimate | 45.64 |
| Beta | 2.80 |
| EPS (TTM) | -2.58 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| FDMT | S&P500 | |
| Current price drop from All-time high | -93.41% | -4.11% |
| Highest price drop | -95.23% | -56.47% |
| Date of highest drop | 8 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -63.90% | -11.06% |
| Avg time to new high | 160 days | 12 days |
| Max time to new high | 1078 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
160.41M
Marketcap category
Small-cap
Description
4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.
Employees
147
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page